New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareDermorphin vs Tesofensine

Dermorphin vs Tesofensine

Side-by-side comparison of key properties, dosing, and research.

Recovery & Repair
Dermorphin
Fat Loss & Metabolic
Tesofensine
Summary
Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
Half-Life
Estimated 30-60 minutes (longer than endorphins due to D-Ala)
8-10 days (exceptionally long; accumulates over weeks)
Admin Route
Subcutaneous (research), Intrathecal (research), Intranasal (research)
Oral
Research
Typical Dose
Not established for human use; research doses vary widely
0.25-0.5 mg per day
Frequency
Not established
Once daily
Key Benefits
  • Potent analgesia superior to morphine on a per-weight basis
  • May reduce perception of fatigue in high-intensity activity
  • Longer-lasting than endogenous opioids due to D-amino acid substitution
  • Research tool for mu-opioid receptor pharmacology
  • Potential therapeutic application in refractory pain
  • Potent appetite suppression via triple monoamine reuptake inhibition
  • Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
  • Increases basal metabolic rate and energy expenditure
  • Reduces fat mass preferentially over lean mass
  • Potential cognitive benefit via dopaminergic and noradrenergic enhancement
  • Longer half-life than sibutramine allows once-daily dosing
Side Effects
  • High addiction and dependence potential (mu-opioid agonism)
  • Respiratory depression at high doses
  • Nausea, vomiting, constipation
  • Sedation and cognitive impairment
  • +2 more
  • Elevated heart rate and blood pressure (sympathomimetic)
  • Dry mouth
  • Insomnia and sleep disturbances
  • Nausea
  • +4 more
Stacks With